TWST vs. PCVX, ASND, ROIV, RVMD, LNTH, BPMC, BBIO, LEGN, ELAN, and CYTK
Should you be buying Twist Bioscience stock or one of its competitors? The main competitors of Twist Bioscience include Vaxcyte (PCVX), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Lantheus (LNTH), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Legend Biotech (LEGN), Elanco Animal Health (ELAN), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry.
Twist Bioscience vs.
Twist Bioscience (NASDAQ:TWST) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, community ranking, dividends and analyst recommendations.
In the previous week, Vaxcyte had 8 more articles in the media than Twist Bioscience. MarketBeat recorded 12 mentions for Vaxcyte and 4 mentions for Twist Bioscience. Vaxcyte's average media sentiment score of 0.70 beat Twist Bioscience's score of 0.56 indicating that Vaxcyte is being referred to more favorably in the news media.
Twist Bioscience has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Twist Bioscience, indicating that it is currently the more affordable of the two stocks.
Twist Bioscience received 56 more outperform votes than Vaxcyte when rated by MarketBeat users. However, 75.00% of users gave Vaxcyte an outperform vote while only 59.06% of users gave Twist Bioscience an outperform vote.
Vaxcyte has a net margin of 0.00% compared to Twist Bioscience's net margin of -66.69%. Vaxcyte's return on equity of -23.53% beat Twist Bioscience's return on equity.
Twist Bioscience currently has a consensus target price of $51.90, indicating a potential upside of 9.13%. Vaxcyte has a consensus target price of $145.71, indicating a potential upside of 70.83%. Given Vaxcyte's stronger consensus rating and higher probable upside, analysts clearly believe Vaxcyte is more favorable than Twist Bioscience.
Twist Bioscience has a beta of 1.85, meaning that its stock price is 85% more volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500.
96.8% of Vaxcyte shares are held by institutional investors. 3.0% of Twist Bioscience shares are held by insiders. Comparatively, 3.1% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Vaxcyte beats Twist Bioscience on 10 of the 16 factors compared between the two stocks.
Get Twist Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for TWST and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Twist Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:TWST) was last updated on 1/21/2025 by MarketBeat.com Staff
